UBS initiates coverage on 6 pharma stocks. Sun Pharma, Cipla among top buys

The report points to weakening trends in both India and the US, with underappreciated growth slowdowns in these markets. UBS has provided a mixed outlook, issuing both 'Buy' and 'Sell' ratings on a range of pharmaceutical stocks.